Evidence map›Paper›PMID 19924281›Full record

Trial reportPloS one2009

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.

John N Waitumbi, Samuel B Anyona, Carol W Hunja, Carolyne M Kifude, Mark E Polhemus, Douglas S Walsh, Chris F Ockenhouse, D Gray Heppner, Amanda Leach, Marc Lievens and 3 more

Open access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. A field trial to assess a blood-stage malaria vaccine.The New England journal of medicine · 2011
    Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Malaria Genomics, Vaccine Development, and Microbiome.Pathogens (Basel, Switzerland) · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. RTS,S/AS01 vaccine (Mosquirix™): an overview.Human vaccines & immunotherapeutics · 2020
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

John N WaitumbiWalter Reed Project, Kenya Medical Research Institute, Kisumu, Kenya. jwaitumbi@wrp-ksm.org
Samuel B Anyona
Carol W Hunja
Carolyne M Kifude
Mark E Polhemus
Douglas S Walsh
Chris F Ockenhouse
D Gray Heppner
Amanda Leach
Marc Lievens
W Ripley Ballou
Joe D Cohen
Colin J Sutherland
Kenya Medical Research Institute · KEGlaxoSmithKline (United Kingdom) · GBWalter Reed Army Institute of Research · USGlaxoSmithKline (Belgium) · BEUnited States Army Medical Research Directorate - Africa · KEUniversity of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in a hybrid protein. The RTS,S antigen is formulated with GSK Biologicals' proprietary Adjuvant Systems AS02(A) or AS01(B). A recent trial of the RTS,S/AS02(A) and RTS,S/AS01(B) vaccines evaluated safety, immunogenicity and impact on the development of parasitemia of the two formulations. Parasite isolates from this study were used to determine the molecular impact of RTS,S/AS02(A) and RTS,S/AS01(B) on the multiplicity of infection (MOI) and the csp allelic characteristics of subsequent parasitemias.

designThe distribution of csp sequences and the MOI of the infecting strains were examined at baseline and in break-through infections from vaccinated individuals and from those receiving a non-malarial vaccine.

settingThe study was conducted in Kombewa District, western Kenya.

participantsSemi-immune adults from the three study arms provided isolates at baseline and during break-through infections. OUTCOME: Parasite isolates used for determining MOI and divergence of csp T cell-epitopes were 191 at baseline and 87 from break-through infections.

resultsGrouping recipients of RTS,S/AS01(A) and RTS,S/AS02(B) together, vaccine recipients identified as parasite-positive by microscopy contained significantly fewer parasite genotypes than recipients of the rabies vaccine comparator (median in pooled RTS,S groups: 3 versus 4 in controls, P = 0.0313). When analyzed separately, parasitaemic individuals in the RTS,S/AS01(B) group, but not the RTS,S/AS02(A) group, were found to have significantly fewer genotypes than the comparator group. Two individual amino acids found in the vaccine construct (Q339 in Th2R and D371 in Th3R) were observed to differ in incidence between vaccine and comparator groups but in different directions; parasites harboring Q339 were less common among pooled RTS,S/AS vaccine recipients than among recipients of rabies vaccine, whereas parasites with D371 were more common among the RTS,S/AS groups.

conclusionsIt is concluded that both RTS,S/AS vaccines reduce multiplicity of infection. Our results do not support the hypothesis that RTS,S/AS vaccines elicit preferential effects against pfcsp alleles with sequence similarity to the 3D7 pfcsp sequence employed in the vaccine construct.

Indexed as

AdolescentAdultAllelesEpitopes, T-LymphocyteFemaleGenotypeHaplotypesHumansMalariaMalaria VaccinesMalePlasmodium falciparumPolymorphism, GeneticSequence Analysis, DNAEpitopes, T-LymphocyteMalaria VaccinesRTS,S-AS01B vaccineRTS,S-AS02A vaccine

Identifiers

PMID19924281
PMCPMC2773849
OpenAlexW2090850868

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.